Table 4 Overview of current and ongoing studies on biological therapies targeting IL17 or IL23 [69–79]
From: The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications
| Biologic | Target | Route | Pso status/trial | PsA status/trial |
|---|---|---|---|---|
| Ustekinumab | Human monoclonal antibody against the p40 subunit of IL-12 and IL-23 | SC | FDA-approved | FDA-approved |
| Secukinumab (AIN457) | Human monoclonal antibody directed against IL17A | IV | Phase III: SIGNATURE | Phase III: FUTURE 1 |
| Brodalumab (AMG-827) | Human monoclonal antibody directed against IL17R | IV | Phase III AMAGINE-1,-2,-3 | |
| Ixekinumab (LY2439821) | Humanized monoclonal antibody directed against IL17A | IV | Phase III: UNCOVER-1,-2,-3 | Phase III: SPIRIT-P1 |